Familial lipoprotein lipase deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:309015OMIM:144250E78.3
Who is this for?
Show terms as
5Active trials5Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Familial lipoprotein lipase (LPL) deficiency is a rare inherited metabolic disorder that affects how your body breaks down fats (triglycerides) in the blood. It is also known as type I hyperlipoproteinemia, familial chylomicronemia syndrome, or hyperlipoproteinemia type Ia. In this condition, the enzyme lipoprotein lipase — which normally breaks down fat-carrying particles called chylomicrons — is either missing or does not work properly. As a result, triglyceride levels in the blood become extremely high, often exceeding 1,000 mg/dL and sometimes reaching over 10,000 mg/dL. The disease usually appears in infancy or early childhood. Key symptoms include repeated episodes of severe abdominal pain caused by inflammation of the pancreas (acute pancreatitis), an enlarged liver and spleen, yellowish fatty deposits under the skin (eruptive xanthomas), and milky-appearing blood due to the high fat content. Some patients also experience fatigue, poor appetite, and failure to thrive in childhood. Treatment has traditionally centered on a very strict low-fat diet, typically limiting dietary fat to 15–20 grams per day or less. Medium-chain triglyceride (MCT) oil supplements may be used because they are absorbed differently and do not require LPL for processing. In 2021, the FDA approved volanesorsen (Waylivra) for certain patients with familial chylomicronemia syndrome in some countries, though access varies. Gene therapy (alipogene tiparvovec, marketed as Glybera) was previously approved in Europe but has since been withdrawn from the market. Managing this condition requires lifelong dietary vigilance and close medical follow-up to prevent life-threatening pancreatitis episodes.

Also known as:

Key symptoms:

Severe abdominal pain from pancreatitisExtremely high triglyceride levels in the bloodMilky or creamy-looking blood (lipemia)Yellowish bumps on the skin (eruptive xanthomas)Enlarged liverEnlarged spleenNausea and vomitingPoor appetiteFailure to thrive in infants and childrenFatigue and low energyRecurrent episodes of pancreatitisAbdominal bloatingMemory or concentration difficulties (brain fog)

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

5 events
Jan 2026CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia

Shanghai Jiao Tong University School of Medicine — EARLY_PHASE1

TrialRECRUITING
Oct 2025CS-121 APOC3 Base Editing in FCS

CorrectSequence Therapeutics Co., Ltd — EARLY_PHASE1

TrialRECRUITING
Feb 2022A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Ionis Pharmaceuticals, Inc. — PHASE3

TrialACTIVE NOT RECRUITING
Nov 2021A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Ionis Pharmaceuticals, Inc. — PHASE3

TrialACTIVE NOT RECRUITING
Dec 2019Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency

Université de Sherbrooke — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Familial lipoprotein lipase deficiency.

5 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

5 recruitingView all trials with filters →
Phase 32 trials
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
Phase 3
Active
· Sites: Huntington Beach, California; Boca Raton, Florida +25 more · Age: 1899 yrs
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
Phase 3
Active
· Sites: Huntington Beach, California; Boca Raton, Florida +9 more · Age: 1899 yrs
N/A1 trial
Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency
N/A
Actively Recruiting
PI: André Carpentier (Université de Sherbrooke) · Sites: Sherbrooke, Quebec · Age: 1875 yrs

Specialists

5 foundView all specialists →
DP
Daniel Gaudet, MD, Ph.D.
Specialist
PI on 1 active trial
RM
Robert Eckel, MD
AURORA, CO
Specialist
PI on 1 active trial
PM
Philippe Moulin, MD
Specialist
PI on 1 active trial
YL
YALIANG LI
Specialist
PI on 2 active trials1783 Familial lipoprotein lipase deficiency publications
AC
André Carpentier
Specialist
PI on 2 active trials20 Familial lipoprotein lipase deficiency publications

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

REDEMPLO

Unknown

Hyperchylomicronemia

Unverified — confirm before calling
copay card
Copay CardPatient Assistance
Accepting applications

Travel Grants

No travel grants are currently matched to Familial lipoprotein lipase deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Familial lipoprotein lipase deficiencyForum →

No community posts yet. Be the first to share your experience with Familial lipoprotein lipase deficiency.

Start the conversation →

Latest news about Familial lipoprotein lipase deficiency

Disease timeline:

New recruiting trial: CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia

A new clinical trial is recruiting patients for Familial lipoprotein lipase deficiency

New recruiting trial: Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency

A new clinical trial is recruiting patients for Familial lipoprotein lipase deficiency

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What should my daily fat intake limit be, and can you refer me to a dietitian experienced with this condition?,What are the warning signs of pancreatitis, and what should I do if they occur?,Am I a candidate for volanesorsen or any other medication to help lower my triglycerides?,How often should I have blood tests to monitor my triglyceride levels and nutritional status?,Are there any clinical trials or new treatments being studied that I might be eligible for?,Should my family members be tested to see if they are carriers?,What fat-soluble vitamin and essential fatty acid supplements should I be taking?

Common questions about Familial lipoprotein lipase deficiency

What is Familial lipoprotein lipase deficiency?

Familial lipoprotein lipase (LPL) deficiency is a rare inherited metabolic disorder that affects how your body breaks down fats (triglycerides) in the blood. It is also known as type I hyperlipoproteinemia, familial chylomicronemia syndrome, or hyperlipoproteinemia type Ia. In this condition, the enzyme lipoprotein lipase — which normally breaks down fat-carrying particles called chylomicrons — is either missing or does not work properly. As a result, triglyceride levels in the blood become extremely high, often exceeding 1,000 mg/dL and sometimes reaching over 10,000 mg/dL. The disease usual

How is Familial lipoprotein lipase deficiency inherited?

Familial lipoprotein lipase deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Familial lipoprotein lipase deficiency typically begin?

Typical onset of Familial lipoprotein lipase deficiency is infantile. Age of onset can vary across affected individuals.

Are there clinical trials for Familial lipoprotein lipase deficiency?

Yes — 5 recruiting clinical trials are currently listed for Familial lipoprotein lipase deficiency on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Familial lipoprotein lipase deficiency?

5 specialists and care centers treating Familial lipoprotein lipase deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Familial lipoprotein lipase deficiency?

1 patient support program are currently tracked on UniteRare for Familial lipoprotein lipase deficiency. See the treatments and support programs sections for copay assistance, eligibility, and contact details.